Latest news about Astonea Labs
Astonea Labs
272.00
-1.95(-0.71%)
Company Performance:
View Company Insights1D-0.71%
1M+69.95%
6M+81.33%
1Y+100.52%
5Y+100.52%
More news about Astonea Labs
09Apr 26
Astonea Labs Limited Submits Quarterly Compliance Certificate for Q4FY26
Astonea Labs Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4FY26, confirming regulatory adherence through its Registrar and Share Transfer Agent, KFIN Technologies Limited. The certificate confirms that all company shares remained in dematerialized form during the quarter ended March 31, 2026, with no rematerialization requests received. The submission demonstrates the company's commitment to regulatory compliance and transparency in shareholder record maintenance.
01Apr 26
Astonea Labs Completes ₹6.25 Crore Acquisition of 25.74% Stake in Damaira Pharmaceuticals
Astonea Labs Limited has successfully completed the acquisition of a 25.74% equity stake in Damaira Pharmaceuticals Private Limited for ₹6.25 crore, utilizing funds from reallocated IPO proceeds. The transaction involved acquiring 52,00,000 equity shares at ₹12.02 per share and represents a strategic investment to expand the company's pharmaceutical sector footprint and create operational synergies.
28Mar 26
Astonea Labs Adopts New Articles of Association at March 27 EGM
Astonea Labs Limited held its Extraordinary General Meeting on March 27, 2026, where shareholders unanimously approved all eight resolutions with 100% votes in favor. The company formally adopted new Articles of Association effective from March 27, 2026, aimed at aligning governance provisions with Companies Act 2013 and SEBI listing requirements while strengthening corporate governance practices.
27Feb 26
Astonea Labs Board Approves IPO Proceeds Variation and Related Party Transactions Worth Rs. 415 Crore
Astonea Labs Limited's board approved variation in IPO proceeds utilization of Rs. 6.25 crore for acquiring 20-21% stake in Damaira Pharmaceuticals Private Limited, representing 16.59% deviation from original objects. The board also granted omnibus approval for material related party transactions worth Rs. 415 crore for FY 2026-27, with major transactions planned with Astonea One Private Limited and other related entities. An Extraordinary General Meeting has been scheduled for 27th March, 2026, to seek shareholder approval for these proposals along with adoption of new Articles of Association and other corporate matters.
26Jan 26
Astonea Labs Limited Incorporates Wholly-Owned US Subsidiary for Pharmaceutical Business Expansion
Astonea Labs Limited has incorporated Astonea LLC, a wholly-owned foreign subsidiary in Wyoming, USA on 25th January, 2026. The subsidiary will focus on pharmaceuticals, food supplements and cosmetics business, with Astonea Labs holding 100% ownership through cash subscription. The incorporation complies with SEBI regulations and establishes the company's presence in the US market for its core business activities.
11Nov 25
Astonea Labs Reports Strong Half-Year Results and Appoints Three New Directors
Astonea Labs Limited announced unaudited financial results for H1 2025, showing a 40.20% year-over-year increase in revenue from operations to Rs 66.29 crores. The company appointed three new Non-Executive, Non-Independent Directors: Mr. Arun Kumar Tripathi, Mr. Pardeep Dalal, and Mr. Vikrant, effective November 10, 2025, subject to shareholder approval. The board also authorized Ms. Pooja Singh to finalize a revised distribution agreement with Astonea One Private Limited.
20Sept 25
Astonea Labs' Company Secretary Resigns, Trading Window to Close
Astonea Labs Limited reported significant corporate changes. Vijay Kumar, Company Secretary and Compliance Officer, resigned effective September 20, 2025. The company also announced the closure of its trading window from October 1, 2025, for insiders and related parties, in compliance with SEBI regulations. This closure will remain until 48 hours after the declaration of Un-Audited Financial Results for the half-year ending September 30, 2025.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,770.30
(-1.10%)
6,564.00
(+0.47%)
4,322.90
(+0.12%)
1,380.70
(+0.10%)
1,067.60
(-0.99%)
1,264.00
(-0.78%)
2,249.40
(-0.02%)
2,304.10
(+0.22%)
1,444.00
(+1.04%)
1,391.90
(+0.67%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
